pharma · Muscle-invasive bladder cancer (MIBC) · Acute ischaemic stroke due to basilar artery occlusion.
Tour Hekla
Tour Hekla is a pharma organization headquartered in EU. Primary therapeutic focus areas include Muscle-invasive bladder cancer (MIBC), Acute ischaemic stroke due to basilar artery occlusion., Thrombotic episodes in supe
Company details
- Status
- Public
- HQ
- Puteaux, Ile de France 92800, FR
- Employees
- 6
- Programs
- 27
- Drugs
- 71
- Patents
- 0
DR230314
Approved · small molecule · Evaluation of the CKD-Epi score to identify a glomerular filtration threshold predictive of morphine failure at usual dosage, using a reference method for assessing renal function: iohexol clearance. All other aspects of the protocol are part of standard care practice.
DR230314 for Evaluation of the CKD-Epi score to identify a glomerular filtration threshold predictive of morphine failure at usual dosage, using a reference method for assessing renal function: iohexol clearance. All other aspects of the protocol are part of standard care practice. is a Approved program (small_molecule) at Tour Hekla with 1 ClinicalTrials.gov record(s).
Internal code DR230314
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Tour Hekla
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Evaluation of the CKD-Epi score to identify a glomerular filtration threshold predictive of morphine failure at usual dosage, using a reference method for assessing renal function: iohexol clearance. All other aspects of the protocol are part of standard care practice.
- Status
- active
- Trials
- 1